VYNE Therapeutics announced a 1-for-50 reverse stock split and a special cash dividend of approximately $0.40242 per share, totaling $17.3 million, in connection with its proposed merger with Yarrow Bioscience. The reverse stock split is expected to reduce outstanding shares from 33.4 million to 0.7 million, and the combined company will trade as Yarrow Bioscience, Inc. under the ticker YARW starting July 27, 2026. Stockholders also approved increasing authorized common stock from 150 million to 300 million shares. VYNE is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immune-mediated conditions.
